drugset
drugset / Trial / NCT02218346

Food Effect Study of AG-221 in Healthy Male Subjects

NCT02218346 ↗

Phase 1 Completed 30 enrolled Agios Pharmaceuticals, Inc. Celgene Corporation · collab
RandomizedCrossoverOpen-labelTreatment

Summary

AG-221 is a first-in-class drug targeted specifically to inhibit the IDH2 enzyme. Small molecule inhibition of the IDH enzyme represents a new, targeted approach to cancer treatment. Administration of oral drugs with food may change the absorption of drugs, and it is therefore useful to characterize the effect of food early in drug development.

Timeline

Start
2014-08
Primary completion
2014-12
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enasidenib Small molecule — Oral

Indications

No indication recorded.